Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0037315 (
sleep apnea
)
8,000
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sleep disorders, including a high incidence of
sleep apnea
, have been recognized as a significant problem in
chronic renal failure
(
CRF
) patients. In a preliminary study, we examined
CRF
patients on maintenance hemodialysis for three nights; one control night, and thereafter randomized to infusion of saline (placebo) for one night and 4% branch-chain amino acid (BCAA) solution for one night. Polysomnographic and respiratory data [respiratory rate, oxygen saturation and end-tidal CO2 (ETCO2)] was recorded continuously throughout the nights and data from each hour compared with baseline (awake) values. The patients studied were characterized by reduced sleep quality and decreased amount of rapid eye movement (REM) sleep. The BCAA infusion was associated with a return of REM sleep to normal and a significant decrease in ETCO2 during both REM and non-REM sleep (P less than 0.05). Our findings demonstrate respiratory stimulation during sleep with infusion of BCAA; this stimulatory effect on respiration (in contrast to many respiratory stimulants) is associated with an increased amount of REM sleep.
...
PMID:Branched-chain amino acid in chronic renal failure patients: respiratory and sleep effects. 178 51
Ambulatory blood pressure monitoring can determine the average blood pressure level and the short- and long-term blood pressure variability (circadian rhythm). The circadian blood pressure rhythm appears to be mediated mainly by the circadian rhythm of the sympathetic tone which is linked to changes in physical and mental activity, e.g. the waking-sleeping cycle. A statistically significant circadian blood pressure rhythm was observed in approximately 80% of mild to moderate essential hypertensive patients as well as in normal subjects. However, in patients with Cushing's syndrome, under glucocorticoid treatment, or with hyperthyroidism, central and/or peripheral autonomic dysfunction (Shy-Drager syndrome, spinal cord injury, brainstem lesions, diabetic neuropathy, uremic neuropathy, etc),
chronic renal failure
, eclampsia, malignant hypertension,
sleep apnea syndrome
or systemic atherosclerosis, the normal circadian blood pressure rhythm appears to be eliminated or reversed, while in those with primary aldosteronism, renovascular hypertension, pheochromocytoma without paroxysmal hypertension, diabetes insipidus, acromegaly, hyperparathyroidism or hyperprolactinemia, the nocturnal blood pressure fall has been observed as in normal subjects. The alteration in the circadian blood pressure rhythm was observed with different pathophysiological conditions, although no specific pattern was observed for any condition. A disturbance in any part of the hierarchy of factors that regulate the circadian rhythm of sympathetic neural tone seems to disturb the circadian blood pressure rhythm. We conclude that ambulatory blood pressure monitoring is not critically important in the diagnosis of secondary hypertension although it does help in screening for secondary hypertension.
...
PMID:Does ambulatory blood pressure monitoring improve the diagnosis of secondary hypertension? 208 1
The daily variation in blood pressure (circadian blood pressure rhythm) is characterized by a nocturnal fall and a diurnal rise. The circadian blood pressure rhythm seems to be mediated mainly by the circadian rhythm of sympathetic tone, linked to changes in physical and mental activities, e.g. the waking-sleeping cycle. Statistically significant circadian blood pressure rhythms have been confirmed in approximately 80% of mild to moderate essential hypertensive patients as well as in normal subjects. However, the normal pattern of circadian blood pressure rhythm is reversed in elderly people and in those with Cushing's syndrome, those undergoing glucocorticoid treatment, and those with hyperthyroidism, central and/or peripheral autonomic dysfunction (Shy-Drager syndrome, tetraplegia, diabetic or uremic neuropathy, etc),
chronic renal failure
, renal or cardiac transplantation, congestive heart failure, eclampsia,
sleep apnea syndrome
, malignant hypertension, systemic atherosclerosis and accelerated hypertensive organ damage. However, in those with primary aldosteronism, renovascular hypertension, pheochromocytoma without paroxysmal hypertension, or those with cardiac pacing, a nocturnal blood pressure fall is ordinarily observed. It may be that a fall in cardiac output rather than in peripheral resistance may be mainly responsible for the nocturnal fall in blood pressure. It also seems that a nocturnal heart rate fall is not responsible for it, since the nocturnal blood pressure fall remained unchanged in patients undergoing cardiac pacing and was disturbed in patients with Cushing's syndrome or hyperthyroidism in whom the circadian heart rate rhythm remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Circadian blood pressure variations under different pathophysiological conditions. 209 80
A high prevalence of
sleep apnea syndrome
has been reported in previous studies of patients with
chronic renal failure
. The possible effects of chronic hemodialysis on the magnitude and severity of
sleep apnea
have not yet been clarified. The present study was undertaken to understand this relationship, by examining subjective and objective measures of sleep on nights following hemodialysis compared to those without hemodialysis. Significant
sleep apnea
was noted in 6 of 11 patients. The percentage of apnea time comprised of obstructive apneas increased significantly on the nights following hemodialysis. No significant differences occurred between these nights in the subjective or EEG measures of sleep, or in the total number of disordered breathing events or level of arterial oxygen desaturation. The association between end-stage renal disease (ESRD) and
sleep apnea syndrome
remains highly significant, but seems not to be acutely altered by conventional hemodialysis treatment.
...
PMID:Effects of hemodialysis on sleep apnea syndrome in end-stage renal disease. 235 61
Changes in the function of the respiratory system are among the frequent complications of
chronic renal failure
whereby their clinical impact is manifested above all in critically ill patients. A typical finding during ventilometric examinations is the limited airflow in the distal airways, and even the clinical picture of obstructive ventilation disorder is not rare. A reduced diffusion capacity of the lungs for CO was found in uraemic patients in long-term dialyzation program as well as after successful renal transplantation. The function of respiratory muscles is characterized by a reduction of the maximal inspiration and expiration pressure. Chronic haemodialyzed patients have a reduced ventilation response to CO2 which may render weaning from the ventilator difficult. In patients with
chronic renal failure
a high prevalence of the
sleep apnoea
syndrome was described. During haemodialysis we can observe alveolar hypoventilation, after its termination we find higher values of dynamic pulmonary volumes, as compared with values before dialysis. Chronic ambulatory peritoneal dialysis creates a prolonged state of iatrogenic ascites and this leads to a reduced residual functional capacity of the lungs, while the configuration of the diaphragm is altered. The author reviews in the submitted paper contemporary findings on the pathogenesis and clinical characteristics of pulmonary functions in patients with
chronic renal failure
.
...
PMID:[Pulmonary function in patients with chronic kidney failure]. 776 95
Complaints about sleep and daytime alertness are common in
ESRD
patients. Eight consecutive
ESRD
patients with a sleep complaint were studied with all-night polysomnography. All were found to have significant
sleep apnea
with a mean apnea/hypopnea index (AHI) of 64 +/- 41.6 episodes per hour of sleep (range 7.5 to 140/hr of sleep). The majority of apneas were of the central or mixed variety causing severe fragmentation of sleep and frequent awakenings. Treatment was attempted with nasal continuous positive airway pressure (NCPAP). NCPAP was highly successful in six of the eight patients, reducing the mean AHI to normal or near normal levels (6.0 +/- 3.8/hr of sleep, P < 0.02 vs. baseline). The quality of sleep was significantly improved with statistically significant decreases in light stage 1 sleep, and nocturnal oxygenation improved with statistically significant increases in low SaO2 values. Five of six responders reported that they awoke feeling more alert and fewer times from sleep. The etiology of
sleep apnea
in
ESRD
is unknown although the frequent central apneas suggest a dysfunction of central respiratory control resulting from the effects of renal failure. Sleep-related complaints in patients with
ESRD
are likely to result from
sleep apnea
, a sleep disorder that can be diagnosed with polysomnography and treated with NCPAP.
...
PMID:Sleep disordered breathing in ESRD: acute beneficial effects of treatment with nasal continuous positive airway pressure. 851 Mar 93
Sleep apnea
is a surprisingly common disorder in end-stage renal disease (ESRD) and
chronic renal failure
. The symptoms of
sleep apnea
frequently go unreported or may be misdiagnosed as uremia, depression, chronic illness, or insomnia. A review of the literature was performed to define the prevalence, morbidity, and treatment of
sleep apnea syndrome
in the ESRD patient.
Sleep apnea
occurs in at least 60% of ESRD patients. The known complications of
sleep apnea
include arrhythmias, pulmonary hypertension, and systemic hypertension. In addition,
sleep apnea
has been implicated in coronary artery disease and strokes. The contribution of
sleep apnea
to the high mortality from cardiac disease and stroke in peritoneal dialysis and hemodialysis patients is unknown. The causes of the increased prevalence of
sleep apnea
in ESRD patients are unknown and likely differ from the general population, but the treatment is similar. The literature suggests that modality of renal replacement therapy does not matter; however, large nocturnal volume peritoneal dialysis may worsen
sleep apnea
. Renal transplantation may be curative. In conclusion,
sleep apnea
may be an under-diagnosed disease in patients on dialysis. There are significant reasons to suspect that
sleep apnea
may worsen the morbidity and mortality of ESRD, and there are potential successful therapies.
...
PMID:Sleep apnea in renal failure. 936 Jun 57
Textbook descriptions of dialysis patients have long included features of insomnia, day-night reversal, and disturbed sleep. Moore recently, a very high prevalence of subjective sleep complaints and specific primary sleep disorders such as
sleep apnea syndrome
, periodic leg movement disorder, and restless legs syndrome have been documented in the population. These problems may in part be responsible for the low rehabilitation rate seen in
ESRD
patients. The purpose of this article is to assist dialysis nurses in their efforts to better understand the sleep alterations experienced by their patients by presenting a succinct review of the research literature. The major topics of discussion include: the prevalence and importance of sleep complaints in dialysis patients; subjective features and related factors; polysomnographic features; and contributing factors.
...
PMID:Sleep and dialysis: a research-based review of the literature. 944 3
This article will familiarize nephrology nurses with the
sleep apnea syndrome
, including its associated risk factors, clinical features, diagnostic strategies, and treatments. A review of the recent research linking
sleep apnea
with
end stage renal disease
(
ESRD
) will also be presented.
...
PMID:Sleep apnea in end stage renal disease. 944 4
End-stage renal disease
(
ESRD
) is commonly associated with complaints of disturbed sleep and sleep disorders, frequently related to periodic limb movements in sleep (PLMS) or
sleep apnea
that may result in daytime sleepiness and other sequelae. Improvements in quality of life, including subjective sleep quality, have been reported in
ESRD
patients treated with recombinant human erythropoietin (rHuEPO). We investigated the objective effects of normalizing hematocrit on sleep disorders, sleep patterns, and daytime ability to remain awake in
ESRD
patients. Ten hemodialysis patients with sleep complaints while on rHuEPO therapy were studied by polysomnography while moderately anemic (mean hematocrit, 32.3%) and again when hematocrit was normalized (mean hematocrit, 42.3%) by increased rHuEPO dosing. Sleep patterns and associated parameters were monitored. Delivered dialysis dose and iron storage factors were monitored. Maintenance of Wakefulness Testing (MWT) was performed to assess daytime alertness/sleepiness. All 10 subjects experienced highly statistically significant reductions in the total number of arousing PLMS (P = 0.002). Nine of 10 subjects showed reductions in both the Arousing PLMS Index (P < 0.01) and the PLMS Index (P = 0.03) when hematocrit was normalized. Measures of sleep quality showed trends to improved quality of sleep. MWT demonstrated significant improvement in the length of time patients were able to remain awake (9.7 versus 17.1 minutes; P = 0.04). RHuEPO therapy with full correction of anemia reduces PLMS, arousals from sleep, and sleep fragmentation while allowing for more restorative sleep and improved daytime alertness. These findings may explain one mechanism for the improved quality-of-life parameters reported in
ESRD
patients treated with rHuEPO.
...
PMID:A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). 1058 19
1
2
3
Next >>